Lifecore Biomedical (LFCR) Stock Overview
Operates as an integrated contract development and manufacturing organization in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
LFCR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lifecore Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.64 |
| 52 Week High | US$8.85 |
| 52 Week Low | US$4.76 |
| Beta | 0.61 |
| 1 Month Change | 12.68% |
| 3 Month Change | 1.87% |
| 1 Year Change | 2.41% |
| 3 Year Change | -8.17% |
| 5 Year Change | -26.18% |
| Change since IPO | -40.08% |
Recent News & Updates
Recent updates
Lifecore Biomedical: A Disconnect Between Share Price And Business Progress
Nov 10Lifecore Biomedical (NASDAQ:LFCR) Is Making Moderate Use Of Debt
Jul 18
A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price
May 02Lifecore Biomedical: We Are Not Playing To Make 5% Or 10% Here
Mar 03
Over 50 New Opportunities Expected From Business Development Expansion
Expanding business development and operational capacity is expected to drive revenue growth by broadening the customer base and enhancing earning potential.Lifecore Biomedical: An Interesting CDMO Pure Play
Dec 01Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward
Nov 26Lifecore Biomedical: Finally A 'Pure Play' CDMO Business
Nov 12Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty
Jun 24White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge
Apr 20Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?
Jun 30Landec Non-GAAP EPS of -$0.32, revenue of $43.35M
Oct 06Landec receives Nasdaq's notification on delayed annual report filing
Sep 09Laughing Water Capital - Landec Corp. : A High Quality CDMO
Jul 27Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt
Jun 24Shareholder Returns
| LFCR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -3.3% | 4.0% | -1.3% |
| 1Y | 2.4% | 2.4% | 8.7% |
Return vs Industry: LFCR underperformed the US Life Sciences industry which returned 2.4% over the past year.
Return vs Market: LFCR underperformed the US Market which returned 8.7% over the past year.
Price Volatility
| LFCR volatility | |
|---|---|
| LFCR Average Weekly Movement | 7.2% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LFCR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LFCR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 406 | Paul Josephs | www.lifecore.com |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of hyaluronate acid (HA) in bulk form, as well as formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. Its product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies.
Lifecore Biomedical, Inc. Fundamentals Summary
| LFCR fundamental statistics | |
|---|---|
| Market cap | US$286.24m |
| Earnings (TTM) | -US$44.36m |
| Revenue (TTM) | US$128.87m |
Is LFCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LFCR income statement (TTM) | |
|---|---|
| Revenue | US$128.87m |
| Cost of Revenue | US$88.57m |
| Gross Profit | US$40.30m |
| Other Expenses | US$84.66m |
| Earnings | -US$44.36m |
Last Reported Earnings
May 25, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 31.27% |
| Net Profit Margin | -34.42% |
| Debt/Equity Ratio | 275.0% |
How did LFCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 19:25 |
| End of Day Share Price | 2025/11/21 00:00 |
| Earnings | 2025/05/25 |
| Annual Earnings | 2025/05/25 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lifecore Biomedical, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Brian Holland | D.A. Davidson & Co. |